Chr t(15;17)
Chr t(15;17)
|
Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia
|
|
PML-RARA fusion
PML-RARA fusion
|
Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia
|
|
No biomarker
No biomarker
|
Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia
|
gemtuzumab ozogamicin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia
|
cytarabine + daunorubicin
Sensitive: A2 - Guideline
|
STAT5b-RARA fusion
STAT5b-RARA fusion
|
Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia
|
DCAG
Sensitive: C4 – Case Studies
|
PML-RARA fusion
PML-RARA fusion
|
Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia
|
cytarabine + idarubicin hydrochloride + tretinoin
Sensitive: C4 – Case Studies
|
FLT3-ITD mutation + PML-RARA fusion + WT1 overexpression
FLT3-ITD mutation + PML-RARA fusion + WT1 overexpression
|
Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia
|
cytarabine + idarubicin hydrochloride + arsenic trioxide + hydroxyurea
Sensitive: C4 – Case Studies
|
ZBTB16-RARA fusion
ZBTB16-RARA fusion
|
Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia
|
chidamide
Sensitive: D – Preclinical
|
STAT5b-RARA fusion
STAT5b-RARA fusion
|
Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia
|
chidamide
Sensitive: D – Preclinical
|
NPM-RARA fusion
NPM-RARA fusion
|
Acute Promyelocytic Leukemia
Acute Promyelocytic Leukemia
|
chidamide
Sensitive: D – Preclinical
|
